Subtle Medical, a leading provider of AI-powered medical imaging software solutions, secured $33 million in growth capital, anchored by a Series C financing led by funds managed by Morgan Stanley Expansion Capital.
The financing included participation from Korea-based Shinhan Venture Investment and existing investors, Fusion Fund, EnvisionX, BRV, and Samsung Ventures, bringing the company’s total capital raised to $86 million.
Subtle Medical intends to use the new capital to accelerate product development efforts, expand commercial adoption globally, and scale its vendor-neutral AI imaging platform across MRI, PET, and CT workflows.
As part of its next phase of growth, the company has appointed industry veteran, Ohad Arazi, as CEO to accelerate global enterprise expansion.
Ohad Arazi brings decades of experience in medical imaging AI, with CEO and leadership roles at Change Healthcare, Zebra Medical Vision, and most recently, Clarius Mobile Health. Enhao Gong, PhD, co-founder and former CEO of Subtle Medical, has transitioned to Chief Science Officer, where he will lead the company’s scientific roadmap and continue supporting operations and strategic partnerships in China.
“What drew me to Subtle is that this isn’t a point solution – it’s becoming the AI layer where health systems run their imaging,” said Ohad Arazi, Chief Executive Officer of Subtle Medical.
“That’s a fundamentally different kind of company, and a bigger opportunity. I’ve spent my career at the intersection of imaging and enterprise software, and I haven’t seen many platforms with this combination of clinical validation and scalability. I’m here to make sure the world knows about it,” added Ohad Arazi.
Subtle Medical is a global leader in AI-powered software that enhances medical imaging quality and efficiency. The company uses deep learning to virtually upgrade existing scanners, allowing for faster scans without sacrificing diagnostic quality. As of today, the company supports more than 1,300 scanners across hospitals and imaging centers globally.
Subtle’s flagship products, SubtleHD (MR) and SubtlePET, are deployed across major imaging networks, academic medical centers, and leading health systems worldwide. Its flagship products have proven to enable up to an 80% reduction in scan time by using deep learning to denoise and sharpen images acquired through accelerated protocols.
Some of the notable customers, including Mount Sinai, RadNet, and Radiology Partners, have reported measurable gains in throughput, efficiency, and patient experience, establishing Subtle as an essential AI infrastructure layer for modern radiology.
Digital health companies, including medical imaging software startups, have secured more than $180 billion in funding to date, according to our recent Funding Database.
More recently, Hypervision Surgical, a medical technology startup developing AI-powered next-generation intelligent surgical imaging systems, raised £17 million in a Series A funding round.
In another deal, SquareMind, a France-based robotics startup developing AI-powered dermatology solutions to make high-quality skin exams more efficient and accessible, raised $18 million in a pre-Series A funding round.